BioSpace News Archive

HANGZHOU, China, March 23, 2020 (GLOBE NEWSWIRE) -- AnHeart Therapeutics, Co., Ltd . (“AnHeart”), a clinical stage oncology company focused on underserved patients in global markets, today announced that its new drug candidate taletrectinib has received IND clearance and Clinical Trial Authorization (CTA) for its two Phase 2 clinical trials from CDE, the Chinese drug evaluation agency. “This is a major milestone for AnHeart. We have an experienced team who has successfully completed techn

The Average Dollar Amount, Per Each Individual E-Commerce Transaction, Increased by 49.10% Sequentially - Over the Previous Week today announced that

IntelGenx Corp. , today announced that it will release its fourth quarter and full-year 2019 financial results before market open on Thursday, March 26, 2020. As previously announced, the U.S. Food and Drug Administration has assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 26, 2020 for completion of its review of IntelGenx’s 505(b)(2) New Drug

- Leading dermatologist, Dr. Elizabeth Tanzi, to present pivotal cellulite trial results -

Eiger BioPharmaceuticals, Inc. today announced that it has completed submission to the U.S. Food and Drug Administration of a new drug application

Capabilities and capacity now available to help customers of all sizes meet increasing demand for new biologics, cell and gene therapies, and drug products

Pliant Therapeutics, Inc., , today announced that it has dosed the first cohort of healthy participants in a first-in-human Phase 1 clinical trial of PLN-1474, a small molecule s

Stoke Therapeutics today reported financial results for the full year ended December 31, 2019, and provided business updates.

Nuclein LLC announces plans to expedite the commercialization of its Nuclein™ Hand-Held PCR Test.

Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that CAPLYTA (lumateperone) is now available to pharmacies in the U.S